Protalix BioTherapeutics (PLX) Current Leases (2019 - 2025)
Historic Current Leases for Protalix BioTherapeutics (PLX) over the last 7 years, with Q3 2025 value amounting to $1.4 million.
- Protalix BioTherapeutics' Current Leases fell 736.07% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 736.07%. This contributed to the annual value of $1.5 million for FY2024, which is 645.85% up from last year.
- Latest data reveals that Protalix BioTherapeutics reported Current Leases of $1.4 million as of Q3 2025, which was down 736.07% from $1.5 million recorded in Q2 2025.
- Over the past 5 years, Protalix BioTherapeutics' Current Leases peaked at $1.5 million during Q3 2024, and registered a low of $1.0 million during Q3 2022.
- Over the past 5 years, Protalix BioTherapeutics' median Current Leases value was $1.3 million (recorded in 2023), while the average stood at $1.3 million.
- Per our database at Business Quant, Protalix BioTherapeutics' Current Leases tumbled by 1902.83% in 2022 and then surged by 3130.0% in 2023.
- Quarter analysis of 5 years shows Protalix BioTherapeutics' Current Leases stood at $1.2 million in 2021, then decreased by 7.37% to $1.1 million in 2022, then increased by 26.03% to $1.4 million in 2023, then rose by 6.46% to $1.5 million in 2024, then decreased by 6.87% to $1.4 million in 2025.
- Its Current Leases was $1.4 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.4 million in Q1 2025.